Key Takeaways
- Flat FY26 guided, but H2 recovery bet placed: Revenue is expected to be broadly in line with FY25, with 60% of sales weighted to H2 as deferred nutraceutical orders and NIP/OTF deliveries materialize.
- EU-GMP suspension is the central constraint: The audit has delayed innovative-led segment sales and forced site transfers; management expects NIP product sales to resume only in Q1 or Q2 of FY27.
- Margins improved sequentially but stay subdued: EBITDA margin rose from 7.9% to 8.8% QoQ on better mix, yet the full-year outlook is for margins to remain constant at these levels through Q3 and Q4.
- Remediation is underway, inspection timeline uncertain: CAPA plans are accepted, consultants are engaged, and the company is targeting audit readiness by Q4, but the reinspection date depends on authorities.
- What to watch next quarter: Whether deferred nutraceutical and NIP/OTF orders actually convert to revenue in H2, progress on site transfer commercial supplies, and any update on the EU-GMP reinspection timeline.
EU-GMP Suspension & Remediation
- Audit findings centered on documentation, not product quality: The auditor conducted an in-depth review of products, dossiers, and manufacturing processes but found no significant observation on product quality or dossier information; the issues stemmed from overreliance on manual documentation.
- Manual documentation being replaced: The company has instituted a switch to electronic data systems with CFR21 compliance that automatically record temperature, humidity and other parameters with fingerprint authentication, addressing the root cause of the HVAC logbook observation.
- CAPA plan accepted by authorities: Three CAPA action taken reports have been submitted with the help of an Indian consultant, and a separate European consultant is oversighting the entire remediation process.
- QA function being strengthened: The quality assurance team is being expanded to better address QMS observations in remediation and future inspections, and suitable changes have been made in training.
- Reinspection timeline is a request, not a commitment: Management expects the inspection around March 2026 but believes it can make a compelling case for an earlier visit due to acute shortage of products like Pancreatin in EU markets; if the primary agency delays, another EU member country where the product is in shortage could be requested to visit.
- Remediation readiness targeted for Q4: The consultant has given a timeline by which the company would be compliant, and by Q4 the company expects to be ready from its end to invite authorities.
Anwar Daud: "We realize that many of these -- the question marks that are raised by different authorities are basically a result of overreliance on manual documentation. The company has instituted a switch..."
Revenue Recovery & H2 Dependence
- H1 was subdued, H2 must deliver: Historically 35-40% of business falls in H1 and the remainder in H2; government orders and most client orders are received in H2, and management expects this pattern to hold.
- Nutraceutical segment dragged Q2: Overall revenue growth was moderated by a decline in the nutraceutical segment due to deferment of domestic institutional orders, which are expected to materialize in Q3 and Q4.
- NIP/OTF decline is timing-related, not structural: The YoY decline reflects an order position effect where two customers who took material in H1 last year are expected to order in H2 this year; management expects the decline to moderate over the next two quarters.
- Base formulation business steady: Earlier currency issues in key markets have been sorted out and the market has become more stable; the base business is expected to compensate for the H1 shortfall and achieve last year's number in H2, with growth in both PFI and formulation fronts supported by new MAs for ROW markets.
- Inventory build-up signals confidence: Inventory days rose from 83 to 109 days, an absolute increase of approximately ₹10 crore, because of a robust order book for Q2 and Q3 and the need to compensate for the first-half shortfall; management expects moderation in Q3 and Q4.
- Innovative product contribution doubled QoQ: Revenue from innovative products rose from ₹46 crores in Q1 to ₹81 crores in Q2, showing consistent progress.
Anwar Daud: "So there was some effect because of the audit because we needed to assess and previously consider whether the observation that has been noted given by the auditors, whether they would actually attract some -- any quality-related issues for all the offerings that we make."
Site Transfers & Alternate Supply
- Tamsulosin + Dutasteride being transferred: This late-stage submission product is being moved to a TGA-approved site; commercial supplies are expected within the next 6 months, with sales possible between Q4 FY26 and Q1 FY27 depending on filing with short-term stability and acceptance by authorities.
- Dimethyl Fumarate MA received in UK: The MA was received by the client based on Zim's dossier; the product will be transferred to a CMO partner, and sales are expected in H2 FY26 as permissions have started coming in from ROW and emerging markets.
- Azithromycin suspension strategy similar: Being executed at EU and MHRA-approved facilities to ensure uninterrupted supply.
- Two alternate contract manufacturing sites arranged: Covering about 3-4 products; these sites have existing accreditation for supplying to EU and Australia, with potentially faster access to MHRA/UK.
- Site transfers carry marginal margin impact: Management acknowledged a marginal impact on margins from contract manufacturing but did not quantify the differential.
- Stability studies required: Product transfers to alternate sites require 3-6 months of stability studies as per market requirements.
Margins & Financials
- EBITDA margin improved sequentially: Rose from 7.9% to 8.8% QoQ driven by better product mix and operational efficiency.
- Margin outlook flat for H2: Management stated margins will remain constant going forward in Q3 and Q4; the decline from prior periods was due to product mix change, lower turnover in H1, and reduction in NIP sales, not consultant or digitization costs.
- H2 volume leverage is the margin mechanism: If 60% of sales come in H2 with fixed and operating costs remaining constant, EBITDA will improve in absolute terms even if the margin percentage stays flat.
- Capex cycle complete: Previously planned capex is now completed with only marginal increases remaining; term loan repayment has already started.
- Working capital to rise with turnover: Management expects working capital to increase commensurate with turnover increase while ratios remain the same.
FY27 Aspiration & Long-Term Levers
- 20-25% growth, 14-15% margin aspiration reaffirmed: Management is sticking to the earlier guidance for FY27, stating only a time difference of 3 to 6 months has occurred; the endeavour is to achieve these levels if everything goes well.
- EU-GMP NIP product sales the key unlock: Sales of NIP products from the EU-GMP facility are expected to start from Q1 or Q2 of FY27, which would restore a high-value revenue stream.
- New marketing authorizations building pipeline: Four new MAs were received this quarter, with commercialization typically taking 3-6 months after MA receipt; two MAs were received this year from TGA and MHRA.
- Off-patent product filings continue: While future MAs cannot be filed from the suspended facility, filings for products going off patent in 2027 and 2028 continue; a 3-4 month delay in filing does not impact the overall filing strategy.
- Pancreatin MA process ongoing: Replies are being given as they come from different EU member countries; the filing process continues and has not been stopped.
- NIP/OTF licensing fees under negotiation: There may be some impact on licensing fees but management is negotiating and hopeful they will remain on the same line as earlier.
Anwar Daud: "During this audit, there was also audit of the products, other data that is relevant to the product and the manufacturing processes. And it was quite an in-depth audit because of how the auditor was looking at the systems existing in the company, but they did not find any observation or any significant observation on the product, the dossier, the product, the information that goes into the product dossier and the quality of the information..."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY26 revenue | Broadly in line with FY25 revenues | FY26 full year |
| FY26 EBITDA margin | Remain constant at current levels through Q3 and Q4 | FY26 H2 |
| Tamsulosin + Dutasteride commercial supplies | From alternate TGA-approved site | Within next 6 months |
| Dimethyl Fumarate sales | From CMO partner in ROW and emerging markets | H2 FY26 |
| Nutraceutical deferred orders | Domestic institutional orders to materialize | Q3 and Q4 FY26 |
| NIP/OTF order position moderation | Decline to moderate as H2 orders deliver | Next 2 quarters |
| EU-GMP NIP product sales | Resume from suspended facility | Q1 or Q2 FY27 |
| EU-GMP reinspection readiness | Company ready from its end per consultant timeline | Q4 FY26 |
| FY27 growth and margin aspiration | 20-25% revenue growth, 14-15% EBITDA margin | FY27, subject to conditions |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Total operating income | ₹88.7 cr, +23.6% QoQ |
| EBITDA | ₹7.8 cr, margin 8.8% vs 7.9% in Q1 FY26 |
| PAT | Loss of ₹0.4 cr, vs loss of ₹1.9 cr in Q1 FY26 |
| Pharma segment revenue | ₹73.2 cr, 83% of total revenue, +30.7% QoQ |
| Nutra segment revenue | ₹15.5 cr, 17% of total revenue; decline due to deferred domestic institutional orders |
| Export revenue | ₹72.8 cr, +21% QoQ |
| Domestic revenue | ₹12.7 cr, broadly stable QoQ |
| NIP and OTF portfolio revenue | ₹8.1 cr |
| Licensing income | ₹2.9 cr |
| R&D investment | ₹7.6 cr |
| Gross contribution margin | 51% in H1 FY26, vs 49.3% in H1 FY25 |
| FY26 revenue guidance | Broadly in line with FY25 revenues |
| Inventory days | 109 days, vs 83 days in prior period; absolute increase of ~₹10 cr |
| Debtor days | 78 to 90 days, normal range |
| Total debt | ~₹120 cr, comprising term loan of ~₹66 cr and cash credit of ~₹51 cr |
| CAPA-related capex | ~₹5 cr, approved by Board |